ORG
RFK Jr.’s Revamped ACIP Votes Against Thimerosal in Flu Vaccines, Signaling Shift in Vaccine Policy
RFK Jr.; ACIP; thimerosal; flu vaccine; vaccine policy; anti-vaccine movement; CDC; RSV shot; Advisory Committee on Immunization Practices
ALTO-203 Misses Depression Endpoint but Shows Positive Biomarker and Cognitive Signals
ALTO-203; Alto Neuroscience; Phase 2 trial; major depressive disorder; EEG biomarkers; theta/beta ratio; attention; wakefulness; William Blair; drug activity; future development
Trump’s CDC Nominee Susan Monarez Affirms Vaccine Safety and Access Commitment
Susan Monarez; CDC nominee; vaccines; Trump administration; vaccine safety; autism; Senate confirmation; Robert F. Kennedy Jr.; Gavi Vaccine Alliance
Novavax Approval Process Raises Concerns Among Former Regulators About FDA Integrity
Novavax; FDA approval; COVID-19 vaccine; regulatory process; integrity concerns; delays; political interference
ACIP Backs Merck’s Enflonsia for RSV Prevention in Infants
ACIP; Merck; Enflonsia; RSV; monoclonal antibody; infants; immunization; Vaccines for Children Program
Altimmune’s Incretin Misses Fibrosis Improvement Endpoints in MASH Trial
Altimmune; incretin; pemvidutide; fibrosis; MASH; GLP-1; clinical trial
Novartis and ProFound Therapeutics Forge $750M-Per-Target Cardiovascular Pact
Novartis; ProFound Therapeutics; cardiovascular disease; biotech partnership; drug discovery; proteomics; biobucks; flagship pioneering; pharmaceutical milestones
Invivyd Highlights Follow-Up to Pemgarda mAb Could Rival COVID Vaccines
Invivyd; Pemgarda; VYD2311; monoclonal antibody; COVID-19; vaccine alternatives; immune compromise; long-acting protection; phase 1/2 clinical data
Longevity Biotech Takes Root on Nasdaq With $180M SPAC Deal
Longevity Biotech; Nasdaq; SPAC deal; public listing; FutureTech II Acquisition Corp.; clinical development; biotech merger; age-related diseases
Bayer’s BlueRock Lays Off 50 Employees, Shuts Cambridge Labs in Streamlining Move
BlueRock Therapeutics; Bayer; layoffs; biotech; Cambridge research labs; cell therapy; streamlining; bemdaneprocel; OpCT-001; pharmaceutical industry